Mylan says that the $100 profit per two-pack of its EpiPen injectors presented by CEO Heather Bresch to Congress last week is actually 60% higher.
Weighing Tesla’s merger offer for SolarCity means separating what can and can’t be measured.
Pfizer said it would remain a single company, deciding not to split into one business focused on patent-protected drugs and another on cash-rich older products.
Whether Donald Trump or Hillary Clinton wins in November, they will enjoy far less latitude to spend money or cut taxes than any president since World War II.
Yum Brands said its board approved the planned spinoff of its China unit, which remains on track to close at the end of next month, as the company also raised its dividend by 11%.
Alaska Air Group said it agreed with the Justice Department that it won’t consummate its planned merger with Virgin America before Oct. 17 to give regulators more time to review the deal.
Williams named two new members to its board and plans to name two more before its annual meeting in November, a move praised by activist investor Corvex Management, which plans to withdraw plans for a proxy contest.
Sales of newly built homes pulled back in August after surging the prior month, a possible sign of weakening momentum across the U.S. housing sector.
Hyundai plants in South Korea were crippled by the first complete strike by unionized workers in more than a decade, threatening to worsen the auto maker’s profit slide.
The question for property and casualty insurers isn’t only whether reinsurance pricing will find a floor but also how much the industry is starting to amplify financial and actuarial risks.